APO Research
Talk to an analyst

APO RESEARCH · REPORT

Afatinib Maleate Tablets

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Afatinib Maleate Tablets Market Analysis and Forecast 2026-2032

29 December 2025194 pages

Choose your research edition.

Industry ResearchAfatinib Maleate Tablets Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Afatinib Maleate Tablets Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Afatinib Maleate Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Afatinib Maleate Tablets Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Afatinib Maleate Tablets Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Afatinib Maleate Tablets market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Afatinib Maleate Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Afatinib Maleate Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Afatinib Maleate Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Afatinib Maleate Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Afatinib Maleate Tablets include Yangtze River Pharm, Qingfeng Medicine Group, Qilu Pharmaceutical, Beacon Pharmaceuticals, Kelun－Kazpharm, Hansoh Pharmaceuticak, Chia Tai-Tianqing and Boehringer Ingelheim International GmbH, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Afatinib Maleate Tablets, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Afatinib Maleate Tablets, also provides the revenue of main regions and countries. Of the upcoming market potential for Afatinib Maleate Tablets, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Afatinib Maleate Tablets revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Afatinib Maleate Tablets market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Afatinib Maleate Tablets revenue, projected growth trends, production technology, application and end-user industry.

Afatinib Maleate Tablets Segment by Company

Yangtze River Pharm

Qingfeng Medicine Group

Qilu Pharmaceutical

Beacon Pharmaceuticals

Kelun－Kazpharm

Hansoh Pharmaceuticak

Chia Tai-Tianqing

Boehringer Ingelheim International GmbH

Afatinib Maleate Tablets Segment by Type

50mg

40mg

30mg

20mg

Afatinib Maleate Tablets Segment by Application

Hospital

Clinic

Others

Afatinib Maleate Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Afatinib Maleate Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Afatinib Maleate Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Afatinib Maleate Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Afatinib Maleate Tablets in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Afatinib Maleate Tablets company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Afatinib Maleate Tablets revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Afatinib Maleate Tablets Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 50mg Major Player Table 3. 40mg Major Player Table 4. 30mg Major Player Table 5. 20mg Major Player Table 6. Global Afatinib Maleate Tablets Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Player Table 8. Clinic Major Player Table 9. Others Major Player Table 10. Afatinib Maleate Tablets Industry Trends Table 11. Afatinib Maleate Tablets Industry Drivers Table 12. Afatinib Maleate Tablets Industry Opportunities and Challenges Table 13. Afatinib Maleate Tablets Industry Restraints Table 14. Global Afatinib Maleate Tablets Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Afatinib Maleate Tablets Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Afatinib Maleate Tablets Market Share by Region (2021-2026) Table 17. Global Afatinib Maleate Tablets Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Afatinib Maleate Tablets Market Share by Region (2027-2032) Table 19. Global Afatinib Maleate Tablets Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Afatinib Maleate Tablets Revenue Market Share by Players (2021-2026) Table 21. Global Afatinib Maleate Tablets Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Afatinib Maleate Tablets Key Players Headquarters & Area Served Table 23. Global Afatinib Maleate Tablets Players, Product Type & Application Table 24. Global Afatinib Maleate Tablets Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Afatinib Maleate Tablets by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Afatinib Maleate Tablets Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Afatinib Maleate Tablets Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Afatinib Maleate Tablets Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Afatinib Maleate Tablets Revenue Market Share by Type (2021-2026) Table 31. Global Afatinib Maleate Tablets Revenue Market Share by Type (2027-2032) Table 32. Global Afatinib Maleate Tablets Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Afatinib Maleate Tablets Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Afatinib Maleate Tablets Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Afatinib Maleate Tablets Revenue Market Share by Application (2021-2026) Table 36. Global Afatinib Maleate Tablets Revenue Market Share by Application (2027-2032) Table 37. Yangtze River Pharm Company Information Table 38. Yangtze River Pharm Business Overview Table 39. Yangtze River Pharm Afatinib Maleate Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Yangtze River Pharm Afatinib Maleate Tablets Product Portfolio Table 41. Yangtze River Pharm Recent Development Table 42. Qingfeng Medicine Group Company Information Table 43. Qingfeng Medicine Group Business Overview Table 44. Qingfeng Medicine Group Afatinib Maleate Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Qingfeng Medicine Group Afatinib Maleate Tablets Product Portfolio Table 46. Qingfeng Medicine Group Recent Development Table 47. Qilu Pharmaceutical Company Information Table 48. Qilu Pharmaceutical Business Overview Table 49. Qilu Pharmaceutical Afatinib Maleate Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Qilu Pharmaceutical Afatinib Maleate Tablets Product Portfolio Table 51. Qilu Pharmaceutical Recent Development Table 52. Beacon Pharmaceuticals Company Information Table 53. Beacon Pharmaceuticals Business Overview Table 54. Beacon Pharmaceuticals Afatinib Maleate Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Beacon Pharmaceuticals Afatinib Maleate Tablets Product Portfolio Table 56. Beacon Pharmaceuticals Recent Development Table 57. Kelun－Kazpharm Company Information Table 58. Kelun－Kazpharm Business Overview Table 59. Kelun－Kazpharm Afatinib Maleate Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Kelun－Kazpharm Afatinib Maleate Tablets Product Portfolio Table 61. Kelun－Kazpharm Recent Development Table 62. Hansoh Pharmaceuticak Company Information Table 63. Hansoh Pharmaceuticak Business Overview Table 64. Hansoh Pharmaceuticak Afatinib Maleate Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Hansoh Pharmaceuticak Afatinib Maleate Tablets Product Portfolio Table 66. Hansoh Pharmaceuticak Recent Development Table 67. Chia Tai-Tianqing Company Information Table 68. Chia Tai-Tianqing Business Overview Table 69. Chia Tai-Tianqing Afatinib Maleate Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Chia Tai-Tianqing Afatinib Maleate Tablets Product Portfolio Table 71. Chia Tai-Tianqing Recent Development Table 72. Boehringer Ingelheim International GmbH Company Information Table 73. Boehringer Ingelheim International GmbH Business Overview Table 74. Boehringer Ingelheim International GmbH Afatinib Maleate Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Boehringer Ingelheim International GmbH Afatinib Maleate Tablets Product Portfolio Table 76. Boehringer Ingelheim International GmbH Recent Development Table 77. North America Afatinib Maleate Tablets Revenue by Type (2021-2026) & (US$ Million) Table 78. North America Afatinib Maleate Tablets Revenue by Type (2027-2032) & (US$ Million) Table 79. North America Afatinib Maleate Tablets Revenue by Application (2021-2026) & (US$ Million) Table 80. North America Afatinib Maleate Tablets Revenue by Application (2027-2032) & (US$ Million) Table 81. North America Afatinib Maleate Tablets Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. North America Afatinib Maleate Tablets Revenue by Country (2021-2026) & (US$ Million) Table 83. North America Afatinib Maleate Tablets Revenue by Country (US$ Million) & (2027-2032) Table 84. Europe Afatinib Maleate Tablets Revenue by Type (2021-2026) & (US$ Million) Table 85. Europe Afatinib Maleate Tablets Revenue by Type (2027-2032) & (US$ Million) Table 86. Europe Afatinib Maleate Tablets Revenue by Application (2021-2026) & (US$ Million) Table 87. Europe Afatinib Maleate Tablets Revenue by Application (2027-2032) & (US$ Million) Table 88. Europe Afatinib Maleate Tablets Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. Europe Afatinib Maleate Tablets Revenue by Country (2021-2026) & (US$ Million) Table 90. Europe Afatinib Maleate Tablets Revenue by Country (US$ Million) & (2027-2032) Table 91. China Afatinib Maleate Tablets Revenue by Type (2021-2026) & (US$ Million) Table 92. China Afatinib Maleate Tablets Revenue by Type (2027-2032) & (US$ Million) Table 93. China Afatinib Maleate Tablets Revenue by Application (2021-2026) & (US$ Million) Table 94. China Afatinib Maleate Tablets Revenue by Application (2027-2032) & (US$ Million) Table 95. Asia Afatinib Maleate Tablets Revenue by Type (2021-2026) & (US$ Million) Table 96. Asia Afatinib Maleate Tablets Revenue by Type (2027-2032) & (US$ Million) Table 97. Asia Afatinib Maleate Tablets Revenue by Application (2021-2026) & (US$ Million) Table 98. Asia Afatinib Maleate Tablets Revenue by Application (2027-2032) & (US$ Million) Table 99. Asia Afatinib Maleate Tablets Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Asia Afatinib Maleate Tablets Revenue by Region (US$ Million) & (2021-2026) Table 101. Asia Afatinib Maleate Tablets Revenue by Region (US$ Million) & (2027-2032) Table 102. SAMEA Afatinib Maleate Tablets Revenue by Type (2021-2026) & (US$ Million) Table 103. SAMEA Afatinib Maleate Tablets Revenue by Type (2027-2032) & (US$ Million) Table 104. SAMEA Afatinib Maleate Tablets Revenue by Application (2021-2026) & (US$ Million) Table 105. SAMEA Afatinib Maleate Tablets Revenue by Application (2027-2032) & (US$ Million) Table 106. SAMEA Afatinib Maleate Tablets Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. SAMEA Afatinib Maleate Tablets Revenue by Country (2021-2026) & (US$ Million) Table 108. SAMEA Afatinib Maleate Tablets Revenue by Country (US$ Million) & (2027-2032) Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Afatinib Maleate Tablets Image Figure 2. Global Afatinib Maleate Tablets Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Afatinib Maleate Tablets Market Size Share 2021 VS 2025 VS 2032 Figure 4. 50mg Image Figure 5. 40mg Image Figure 6. 30mg Image Figure 7. 20mg Image Figure 8. Global Afatinib Maleate Tablets Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Afatinib Maleate Tablets Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Others Image Figure 13. Global Afatinib Maleate Tablets Market Size (US$ Million) & (2021-2032) Figure 14. Global Afatinib Maleate Tablets Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Afatinib Maleate Tablets Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Afatinib Maleate Tablets Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Afatinib Maleate Tablets Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Afatinib Maleate Tablets Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Afatinib Maleate Tablets Revenue Market Share by Type (2021-2032) Figure 21. Global Afatinib Maleate Tablets Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Afatinib Maleate Tablets Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Afatinib Maleate Tablets Revenue Market Share by Application (2021-2032) Figure 24. North America Afatinib Maleate Tablets Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Afatinib Maleate Tablets Revenue Share by Type (2021-2032) Figure 26. North America Afatinib Maleate Tablets Revenue Share by Application (2021-2032) Figure 27. North America Afatinib Maleate Tablets Revenue Share by Country (2021-2032) Figure 28. United States Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Afatinib Maleate Tablets Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Afatinib Maleate Tablets Revenue Share by Type (2021-2032) Figure 33. Europe Afatinib Maleate Tablets Revenue Share by Application (2021-2032) Figure 34. Europe Afatinib Maleate Tablets Revenue Share by Country (2021-2032) Figure 35. Germany Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Afatinib Maleate Tablets Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Afatinib Maleate Tablets Revenue Share by Type (2021-2032) Figure 45. China Afatinib Maleate Tablets Revenue Share by Application (2021-2032) Figure 46. Asia Afatinib Maleate Tablets Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Afatinib Maleate Tablets Revenue Share by Type (2021-2032) Figure 48. Asia Afatinib Maleate Tablets Revenue Share by Application (2021-2032) Figure 49. Asia Afatinib Maleate Tablets Revenue Share by Region (2021-2032) Figure 50. Japan Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Afatinib Maleate Tablets Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Afatinib Maleate Tablets Revenue Share by Type (2021-2032) Figure 58. SAMEA Afatinib Maleate Tablets Revenue Share by Application (2021-2032) Figure 59. SAMEA Afatinib Maleate Tablets Revenue Share by Country (2021-2032) Figure 60. Brazil Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Afatinib Maleate Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • 50mg
  • 40mg
  • 30mg
  • 20mg
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Yangtze River Pharm
  • Qingfeng Medicine Group
  • Qilu Pharmaceutical
  • Beacon Pharmaceuticals
  • Kelun－Kazpharm
  • Hansoh Pharmaceuticak
  • Chia Tai-Tianqing
  • Boehringer Ingelheim International GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Afatinib Maleate Tablets Market by Type
  3. 1.2.1 Global Afatinib Maleate Tablets Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 50mg
  5. 1.2.3 40mg
  6. 1.2.4 30mg
  7. 1.2.5 20mg
  8. 1.3 Afatinib Maleate Tablets Market by Application
  9. 1.3.1 Global Afatinib Maleate Tablets Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Afatinib Maleate Tablets Market Dynamics
  1. 2.1 Afatinib Maleate Tablets Industry Trends
  2. 2.2 Afatinib Maleate Tablets Industry Drivers
  3. 2.3 Afatinib Maleate Tablets Industry Opportunities and Challenges
  4. 2.4 Afatinib Maleate Tablets Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Afatinib Maleate Tablets Market Perspective (2021-2032)
  2. 3.2 Global Afatinib Maleate Tablets Growth Trends by Region
  3. 3.2.1 Global Afatinib Maleate Tablets Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Afatinib Maleate Tablets Market Size by Region (2021-2026)
  5. 3.2.3 Global Afatinib Maleate Tablets Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Afatinib Maleate Tablets Revenue by Players
  2. 4.1.1 Global Afatinib Maleate Tablets Revenue by Players (2021-2026)
  3. 4.1.2 Global Afatinib Maleate Tablets Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Afatinib Maleate Tablets Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Afatinib Maleate Tablets Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Afatinib Maleate Tablets Key Players Headquarters & Area Served
  7. 4.4 Global Afatinib Maleate Tablets Players, Product Type & Application
  8. 4.5 Global Afatinib Maleate Tablets Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Afatinib Maleate Tablets Market CR5 and HHI
  11. 4.6.3 2025 Afatinib Maleate Tablets Tier 1, Tier 2, and Tier 3
5 Afatinib Maleate Tablets Market Size by Type
  1. 5.1 Global Afatinib Maleate Tablets Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Afatinib Maleate Tablets Revenue by Type (2021-2032)
  3. 5.3 Global Afatinib Maleate Tablets Revenue Market Share by Type (2021-2032)
6 Afatinib Maleate Tablets Market Size by Application
  1. 6.1 Global Afatinib Maleate Tablets Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Afatinib Maleate Tablets Revenue by Application (2021-2032)
  3. 6.3 Global Afatinib Maleate Tablets Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Yangtze River Pharm
  2. 7.1.1 Yangtze River Pharm Company Information
  3. 7.1.2 Yangtze River Pharm Business Overview
  4. 7.1.3 Yangtze River Pharm Afatinib Maleate Tablets Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Yangtze River Pharm Afatinib Maleate Tablets Product Portfolio
  6. 7.1.5 Yangtze River Pharm Recent Developments
  7. 7.2 Qingfeng Medicine Group
  8. 7.2.1 Qingfeng Medicine Group Company Information
  9. 7.2.2 Qingfeng Medicine Group Business Overview
  10. 7.2.3 Qingfeng Medicine Group Afatinib Maleate Tablets Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Qingfeng Medicine Group Afatinib Maleate Tablets Product Portfolio
  12. 7.2.5 Qingfeng Medicine Group Recent Developments
  13. 7.3 Qilu Pharmaceutical
  14. 7.3.1 Qilu Pharmaceutical Company Information
  15. 7.3.2 Qilu Pharmaceutical Business Overview
  16. 7.3.3 Qilu Pharmaceutical Afatinib Maleate Tablets Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Qilu Pharmaceutical Afatinib Maleate Tablets Product Portfolio
  18. 7.3.5 Qilu Pharmaceutical Recent Developments
  19. 7.4 Beacon Pharmaceuticals
  20. 7.4.1 Beacon Pharmaceuticals Company Information
  21. 7.4.2 Beacon Pharmaceuticals Business Overview
  22. 7.4.3 Beacon Pharmaceuticals Afatinib Maleate Tablets Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Beacon Pharmaceuticals Afatinib Maleate Tablets Product Portfolio
  24. 7.4.5 Beacon Pharmaceuticals Recent Developments
  25. 7.5 Kelun－Kazpharm
  26. 7.5.1 Kelun－Kazpharm Company Information
  27. 7.5.2 Kelun－Kazpharm Business Overview
  28. 7.5.3 Kelun－Kazpharm Afatinib Maleate Tablets Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Kelun－Kazpharm Afatinib Maleate Tablets Product Portfolio
  30. 7.5.5 Kelun－Kazpharm Recent Developments
  31. 7.6 Hansoh Pharmaceuticak
  32. 7.6.1 Hansoh Pharmaceuticak Company Information
  33. 7.6.2 Hansoh Pharmaceuticak Business Overview
  34. 7.6.3 Hansoh Pharmaceuticak Afatinib Maleate Tablets Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Hansoh Pharmaceuticak Afatinib Maleate Tablets Product Portfolio
  36. 7.6.5 Hansoh Pharmaceuticak Recent Developments
  37. 7.7 Chia Tai-Tianqing
  38. 7.7.1 Chia Tai-Tianqing Company Information
  39. 7.7.2 Chia Tai-Tianqing Business Overview
  40. 7.7.3 Chia Tai-Tianqing Afatinib Maleate Tablets Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Chia Tai-Tianqing Afatinib Maleate Tablets Product Portfolio
  42. 7.7.5 Chia Tai-Tianqing Recent Developments
  43. 7.8 Boehringer Ingelheim International GmbH
  44. 7.8.1 Boehringer Ingelheim International GmbH Company Information
  45. 7.8.2 Boehringer Ingelheim International GmbH Business Overview
  46. 7.8.3 Boehringer Ingelheim International GmbH Afatinib Maleate Tablets Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Boehringer Ingelheim International GmbH Afatinib Maleate Tablets Product Portfolio
  48. 7.8.5 Boehringer Ingelheim International GmbH Recent Developments
8 North America
  1. 8.1 North America Afatinib Maleate Tablets Revenue (2021-2032)
  2. 8.2 North America Afatinib Maleate Tablets Revenue by Type (2021-2032)
  3. 8.2.1 North America Afatinib Maleate Tablets Revenue by Type (2021-2026)
  4. 8.2.2 North America Afatinib Maleate Tablets Revenue by Type (2027-2032)
  5. 8.3 North America Afatinib Maleate Tablets Revenue Share by Type (2021-2032)
  6. 8.4 North America Afatinib Maleate Tablets Revenue by Application (2021-2032)
  7. 8.4.1 North America Afatinib Maleate Tablets Revenue by Application (2021-2026)
  8. 8.4.2 North America Afatinib Maleate Tablets Revenue by Application (2027-2032)
  9. 8.5 North America Afatinib Maleate Tablets Revenue Share by Application (2021-2032)
  10. 8.6 North America Afatinib Maleate Tablets Revenue by Country
  11. 8.6.1 North America Afatinib Maleate Tablets Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Afatinib Maleate Tablets Revenue by Country (2021-2026)
  13. 8.6.3 North America Afatinib Maleate Tablets Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Afatinib Maleate Tablets Revenue (2021-2032)
  2. 9.2 Europe Afatinib Maleate Tablets Revenue by Type (2021-2032)
  3. 9.2.1 Europe Afatinib Maleate Tablets Revenue by Type (2021-2026)
  4. 9.2.2 Europe Afatinib Maleate Tablets Revenue by Type (2027-2032)
  5. 9.3 Europe Afatinib Maleate Tablets Revenue Share by Type (2021-2032)
  6. 9.4 Europe Afatinib Maleate Tablets Revenue by Application (2021-2032)
  7. 9.4.1 Europe Afatinib Maleate Tablets Revenue by Application (2021-2026)
  8. 9.4.2 Europe Afatinib Maleate Tablets Revenue by Application (2027-2032)
  9. 9.5 Europe Afatinib Maleate Tablets Revenue Share by Application (2021-2032)
  10. 9.6 Europe Afatinib Maleate Tablets Revenue by Country
  11. 9.6.1 Europe Afatinib Maleate Tablets Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Afatinib Maleate Tablets Revenue by Country (2021-2026)
  13. 9.6.3 Europe Afatinib Maleate Tablets Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Afatinib Maleate Tablets Revenue (2021-2032)
  2. 10.2 China Afatinib Maleate Tablets Revenue by Type (2021-2032)
  3. 10.2.1 China Afatinib Maleate Tablets Revenue by Type (2021-2026)
  4. 10.2.2 China Afatinib Maleate Tablets Revenue by Type (2027-2032)
  5. 10.3 China Afatinib Maleate Tablets Revenue Share by Type (2021-2032)
  6. 10.4 China Afatinib Maleate Tablets Revenue by Application (2021-2032)
  7. 10.4.1 China Afatinib Maleate Tablets Revenue by Application (2021-2026)
  8. 10.4.2 China Afatinib Maleate Tablets Revenue by Application (2027-2032)
  9. 10.5 China Afatinib Maleate Tablets Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Afatinib Maleate Tablets Revenue (2021-2032)
  2. 11.2 Asia Afatinib Maleate Tablets Revenue by Type (2021-2032)
  3. 11.2.1 Asia Afatinib Maleate Tablets Revenue by Type (2021-2026)
  4. 11.2.2 Asia Afatinib Maleate Tablets Revenue by Type (2027-2032)
  5. 11.3 Asia Afatinib Maleate Tablets Revenue Share by Type (2021-2032)
  6. 11.4 Asia Afatinib Maleate Tablets Revenue by Application (2021-2032)
  7. 11.4.1 Asia Afatinib Maleate Tablets Revenue by Application (2021-2026)
  8. 11.4.2 Asia Afatinib Maleate Tablets Revenue by Application (2027-2032)
  9. 11.5 Asia Afatinib Maleate Tablets Revenue Share by Application (2021-2032)
  10. 11.6 Asia Afatinib Maleate Tablets Revenue by Country
  11. 11.6.1 Asia Afatinib Maleate Tablets Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Afatinib Maleate Tablets Revenue by Country (2021-2026)
  13. 11.6.3 Asia Afatinib Maleate Tablets Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Afatinib Maleate Tablets Revenue (2021-2032)
  2. 12.2 SAMEA Afatinib Maleate Tablets Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Afatinib Maleate Tablets Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Afatinib Maleate Tablets Revenue by Type (2027-2032)
  5. 12.3 SAMEA Afatinib Maleate Tablets Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Afatinib Maleate Tablets Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Afatinib Maleate Tablets Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Afatinib Maleate Tablets Revenue by Application (2027-2032)
  9. 12.5 SAMEA Afatinib Maleate Tablets Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Afatinib Maleate Tablets Revenue by Country
  11. 12.6.1 SAMEA Afatinib Maleate Tablets Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Afatinib Maleate Tablets Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Afatinib Maleate Tablets Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst